Spelling suggestions: "subject:"lewis foodgroup atemsystem"" "subject:"lewis foodgroup systsystem""
1 |
Helicobacter pylori molecular mechanisms for variable adherence properties /Vallström, Anna, January 2009 (has links)
Diss. (sammanfattning) Umeå : Umeå universitet, 2009. / Härtill 4 uppsatser.
|
2 |
Sistemas Histo-sanguíneos ABO, Secretor e Lewis como fatores de risco para a espondilite anquilosante.Camargo, Ulisses 22 September 2016 (has links)
Submitted by Fabíola Silva (fabiola.silva@famerp.br) on 2018-02-07T18:29:25Z
No. of bitstreams: 1
ulissescamargo_tese.pdf: 700757 bytes, checksum: 68231dab9197a8717320c0e887f2b2f6 (MD5) / Made available in DSpace on 2018-02-07T18:29:25Z (GMT). No. of bitstreams: 1
ulissescamargo_tese.pdf: 700757 bytes, checksum: 68231dab9197a8717320c0e887f2b2f6 (MD5)
Previous issue date: 2016-09-22 / Introduction. The spondyloarthritis encomprises a group of diseases strongly
associated with HLA-B*27 gene. It has been proposed that genes not belonging to the
major histocompatibility complex human influence the genesis of these diseases
especially in patients HLA-B*27 negative. Objectives. The aim of this study was to test
the hypothesis that the antigens of the ABO, Secretor and Lewis histo-blood systems are
associated with spondyloarthritis, especially ankylosing spondylitis (AS). Material and
methods. Three hundred and ninety-four patients with clinical suspicion of
spondyloarthritis sent for identification of HLA-B*27 gene were analyzed. One hundred
and nineteen (30.2%) had confirmed the diagnosis of spondyloarthritis according to the
ASAS criteria. The remaining 275 (69.8%) were used as controls. The identification of
HLA-B*27 gene was performed using the PCR-SSOP method. The identification of the
antigens of the ABO, Secretor and Lewis histo-blood systems was performed using
hemagglutination and PCR-RFLP methods. The exact Fisher's test, the chi-square, and
the values of Odds Ratio (OR) and Confidence Interval set at 95% were calculated using
the GraphPad INSTAT software, accepting the error of 5%. Results. No statistically
significant differences were observed in the frequency of antigenic profiles of ABO (χ2:
1.152; p = 0.764; GL: 3), Secreto (χ2: 0.779; p = 0.377; GL: 1) and Lewis (χ2: 1.853; p
= 0.396; GL: 2) histo-blood groups between patients and controls. The Lea antigen was
more frequent in patients with AS compared to controls (OR: 1.833; 95% CI: 1025-
3284, p = 0.053). This antigen was strongly associated with AS in HLA-B*27 negative
patients compared to controls (OR: 4.469; 95% CI: 1931-10342; p = 0.0007). This
association remained only in males in the absence of HLA-B*27 gene (OR: 6.880; 95%
CI: 1852-25564; p = 0.004). Conclusions. AS is associated to the Lea antigen in HLAB*
27 negative male patients. / Introdução. As espondiloartrites compreendem um grupo de doenças fortemente
associadas ao gene HLA-B*27. Tem sido proposto que genes não pertencentes ao
complexo principal de histocompatibilidade humano influenciam a gênese destas
doenças especialmente nos pacientes HLA-B*27 negativos. Objetivos. O objetivo deste
estudo foi testar a hipótese de que os antígenos dos sistemas histo-sanguíneos ABO,
Secretor e Lewis estão associados à espondiloartrites, especialmente a espondilite
anquilosante (EA). Material e método. Foram analisados 394 pacientes com suspeita
clínica de espondiloartrites encaminhados para identificação do gene HLA-B*27. Cento
e dezenove (30,2%) tiveram o diagnóstico de espondiloartrite confirmado de acordo
com os critérios ASAS. Os 275 (69,8%) restantes compuseram o grupo controle. A
identificação do gene HLA-B*27 foi realizada com o uso do método PCR-SSOP. A
caracterização dos antígenos dos sistemas histo-sanguíneos ABO, Secretor e Lewis foi
realizada com o uso dos métodos hemaglutinação e PCR-RFLP. O teste exato de Fisher,
o qui-quadrado, os valores de Odds Ratio (OR) e do intervalo de confiança a 95% foram
calculados com o uso do software GraphPad Instat, aceitando o erro de 5%. Resultados.
Não foram observadas diferenças estatisticamente significantes nas frequências dos
perfis antigênicos dos sistemas histo-sanguíneos ABO (χ2: 1.152; p=0,764; GL: 3),
Secretor (χ2: 0.779; p=0,377; GL: 1) e Lewis (χ2: 1.853; p=0,396; GL: 2) de pacientes e
controles. Foi observada maior frequência do antígeno Lea em pacientes com EA,
comparados aos controles (OR: 1.833; IC 95%: 1.025 – 3.284; p=0,053). Este antígeno
mostrou-se fortemente associado à EA em pacientes HLA-B*27 negativos comparados
aos controles (OR: 4.469; IC 95%: 1.931 – 10.342; p=0,0007). Esta associação se
manteve apenas no gênero masculino na ausência do gene HLA-B*27 (OR: 6.880; IC
95%: 1.852 – 25.564; p = 0,004). Conclusões. A EA está associada ao antígeno Lea nos
pacientes masculinos HLA-B*27 negativos.
|
3 |
Characterisation of surface traits of Helicobacter pylori and their role in the infectious process /Petersson, Christoffer January 2003 (has links) (PDF)
Diss. Linköping : Univ., 2003.
|
4 |
Associação entre os sistemas histo-sanguíneos ABO, Secretor e Lewis e as formas clínicas da Doença de ChagasBernardo, Cássia Rubia 27 February 2014 (has links)
Submitted by Fabíola Silva (fabiola.silva@famerp.br) on 2016-10-03T19:51:39Z
No. of bitstreams: 1
cassiarubiabernardo_dissert.pdf: 1967854 bytes, checksum: 8824de8e39f94d01de50b4ffdbee4e9c (MD5) / Made available in DSpace on 2016-10-03T19:51:39Z (GMT). No. of bitstreams: 1
cassiarubiabernardo_dissert.pdf: 1967854 bytes, checksum: 8824de8e39f94d01de50b4ffdbee4e9c (MD5)
Previous issue date: 2014-02-27 / Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP / Introduction: Chagas disease is caused by the protozoan Trypanosoma cruzi, which is transmitted to humans commonly in the feces of a hemipterous popularly known as barber. The natural infection occurs mainly in childhood. After a period of approximately two decades infected individuals develop clinical manifestations such as Chagas heart disease and Chagas gastrointestinal disease (Megaesophagus and/or Megacolon). The expression of the antigens belonging to histo-blood systems ABO, Secretor and Lewis, controlled by the genes ABO (9q34.1), FUT2 (19q13.3) and FUT3 (19p13.3) differs between the organs affected by Chagas disease. It is possible that the differential tissue expression of ABO, Secretor and Lewis histo-blood groups influences the clinical manifestations of Chagas disease. Aim: The aim if this study was to verify if the antigens of the histo-blood systems ABO, Secretor and Lewis are associated with different clinical forms of Chagas disease. Materials and methods: After obtaining the informed consent peripheral blood and serum samples from 827 individuals were collected. Patients were divided into three subgroups according to their clinical state (megacólon [n=66], megaesophagus [n=119] and cardiomyopathy [n=154]). The control group consisted of 488 blood donors properly fit for the donation. The Lewis and ABO phenotyping were performed by hemagglutination test tube and gel columns agglutination, respectively. The IgG anti-T. cruzi antibodies were identified by ELISA. FUT2 and FUT3 genotyping were carried out by PCR-RFLP. Results: The mean age of patients with Chagas disease was 64.8±11.2 and blood donors 34.3±11.0 (p<0.0001). The differences between the percentages of the sex of the patients and donors were statistically significant (p <0.0001). The frequencies of ABO, Secretor and Lewis distributed in the three forms of the disease compared with each other and with donors, did not give differences statistically significant. The comparison between the ABO and Secretor combined, according to the three forms of Chagas disease, showed statistically significant differences for megaesophagus form (p=0.015). The frequencies of ABO, Secretor and Lewis antigen profiles between patients and donors showed differences statistically significant in favor of BLeb antigen (p=0.032). Conclusion: The results suggest that the high expression of antigen B, which characterizes the B and AB blood groups under the control of functional FUT2 (Secretor) gene acts as a risk factor for megaesophagus form of the Chagas disease. / Introdução: A doença de Chagas é causada pelo protozoário Trypanosoma cruzi, o qual é transmitido ao homem, comumente, pelas fezes de um hemíptero conhecido popularmente como barbeiro. A infecção natural ocorre principalmente na infância e após um período aproximado de duas décadas, parte dos indivíduos infectados desenvolvem manifestações clínicas como a Cardiopatia Chagásica Crônica e a doença do trato gastrointestinal (Megaesôfago e/ou Megacólon). A expressão dos antígenos dos sistemas histo-sanguíneos ABO, Secretor e Lewis, controlada pelos genes ABO (9q34.1), FUT2 (19q13.3) e FUT3 (19p13.3), difere entre os órgãos acometidos por esta doença e pode influenciar suas manifestações clínicas. Objetivo: Avaliar se os antígenos dos sistemas histo-sanguíneos ABO, Secretor e Lewis estão associados às diferentes formas clínicas da Doença de Chagas. Materiais e Métodos: Após a entrevista e obtenção do termo de consentimento livre e esclarecido, amostras de sangue periférico e soro de 827 indivíduos foram analisadas. Os pacientes com a forma crônica da Doença de Chagas foram divididos em três subgrupos de acordo com a forma clínica, (megacólon=66, megaesôfago=119 e cardiomiopatia=154). O grupo controle constitui-se de 488 doadores de sangue devidamente aptos à doação. As fenotipagens ABO e Lewis foram realizadas por métodos de hemaglutinação em tubos e colunas de gel, respectivamente. A pesquisa de anticorpos da classe IgG anti-T. cruzi foi realizada pelo teste de ELISA. Os genótipos FUT2 e FUT3 foram identificados por PCR-RFLP. Resultados: A média de idade dos pacientes chagásicos foi de 64,8±11,2 e dos doadores de sangue 34,3±11,0 (p<0.0001). As diferenças entre as porcentagens do sexo dos pacientes e doadores foram estatisticamente significantes (p< 0.0001). As frequências dos fenótipos ABO, Secretor e Lewis distribuídos nas três formas da doença comparados entre si e com os doadores, não revelaram diferenças estatisticamente significantes. A comparação entre os fenótipos ABO e Secretor combinados, de acordo com as três formas da Doença de Chagas, mostrou diferenças estatisticamente significantes para a forma megaesôfago (p=0,015). A comparação entre as frequências dos perfis antigênicos de pacientes e doadores, revelaram diferença estatisticamente significante para o perfil de antígenos BLeb (p=0,032). Conclusões: Os resultados sugerem que a expressão do antígeno carboidrato B, o qual caracteriza os grupos sanguíneos B e AB, cuja síntese está sob o controle dos genes funcionais FUT2 (Secretor), atua como um fator de risco para a forma megaesôfago da Doença de Chagas.
|
5 |
Značaj testa inhibicije hemaglutinacije pljuvačke i Lewis fenotipa u ispitivanju udruženosti sekretornog statusa i seronegativnih spondiloartropatija / The significance of the hemagglutination inhibition test of saliva and Lewis phenotype in the study of association between secretory status and seronegative spondyloarthropathies.Busarčević Ivan 22 February 2017 (has links)
<p>Uvod: Pojam "sekretor” ili „nesekretor" se odnosi na sposobnost pojedinca da luči antigene krvnih grupa ABO sistema u telesnim tečnostima. Određivanje ABO krvne grupe i sekretornog statusa, testom inhibicije hemaglutinacije pljuvačke i Lewis fenotipa na eritrocitima su važni u kliničkoj i forenzičkoj medicini, u odnosu na etiopatogenezu mnogih bolesti. Nesekretorstvo ABO krvnogrupne supstance je udruženo sa češćom pojavom autoimunih inflamatornih oboljenja među kojima su i seronegativne spondiloartropatije. Veća učestalost seronegativnih spondiloartropatija među osobama koje imaju HLA-B27 antigen predstavlja polaznu osnovu stanovišta da genetski faktori u kombinaciji sa faktorima sredine utiču na pojavu seronegativnih spondiloartropatija u genetski predisponiranih individua. Teza istražuje značaj testa inhibicije hemaglutinacije plijuvačke i određivanja ABO i Lewis fenotipa na eritrocitim u dijagnostici seronegativnih spondiloartropatija. Ciljevi i hipoteze: Cilj istraživanja je bio da se utvrdi učestalost nesekretora i sekretora ABO krvnogrupne supstance i Lewis fenotipa u grupi obolelih od seronegativnih spondiloartropatija i izvršiti poređenje rezultata u odnosu na grupu zdravih ispitanka. Pretpostavljeno je da postoji značajno veći broj nesekretora ABO krvnogrupne supstance u obolelih od seronegativnih spondiloartropatija u odnosu na zdrave ispitanike. Pretpostavljeno je i da postoji značajno veća učestalost nesekretora ABO krvnogrupne supstance u obolelih od seronegativnih spondiloartropatija sa negativnim HLA-B27 antigenom. Pretpostavljeno je da kod osoba obolelih od seronegativnih spondiloartropatija dolazi do promene Lewis fenotipa na eritrocitima u odnosu na sekretorni status u pljuvačci. Metode: Sprovedena je longitudinalna prospektibvna studija. Ispitanici stariji od šest godina oba pola podeljeni su u dve randomizovane grupe. Eksperimentalnu grupu sačinjavalo je 110 ispitanika sa dijagnozom oboljenja iz grupe seronegativnih spondiloartropatija. Kontrolnu grupu sačinjavalo je 103 dobrovoljna davaoca krvi, bez dijaghnoze oboljenja iz grupe seronegativnih spondiloartropatija. Ispitanicima kontrolne i eksperimentalne grupe određena je pripadnosti ABO krvnogrupnom sistemu, sekretorni status i Lewis fenotip, dok je osobama eksperimentalne grupe određen i fenotip HLA-B27. Uključujući kriterijumi osim navedenog bili su da ispitivane osobe ženskog pola nisu trudinice i da ispitanici obe grupe nisu primali transfuziju krvi tri meseca pre uključivanja u istraživanje. Rezultati: Rezultati istraživanja ukazuju da nesekretori ABO krvnogrupne supstance imaju 1,63 puta veći rizik (veću učestalost), oboljevanja od seronegativnih spondiloartropatija u odnosu na zdravu populaciju ispitanika, kao i da smanjena ekspresija Lewis (b) antigena predstavlja doprinoseći faktor razvoja seronegativnih spondiloartropatija. Ustanovljeno je da pod uticajem seronegativnih spondiloartropatija dolazi do izmene Lewis fenotipa na eritrocitima obolelih. Verovatnoća dokazivanja oboljenja iz grupe seronegativnih spondilartropatija među obolelima veća je za 11% kod nesekretora fenotipa HLA-B27- u odnosu na obolele nesekretore fenotipa HLA-B27+. Zaključak: Sekretorni status i Lewis fenotip predstavljaju zasebne dijagnostičke biohemijske markere nezavisne od HLA-B27 antigena koji doprinose ranijem otkrivanju osoba koje imaju predispoziciju razvoja oboljenja iz grupe seronegativnih spondiloartropatija.</p> / <p>Introduction:The term secretory state referes to ability of individual to secrete ABO blood group antigens in body fluids. Determination of the ABO blood group antigens and secretory status by hemagglutionation inhibition test using saliva as well as Lewis phenotype on erythrocytes are important in clinical and forensic medicine, in relation to the etiopathogenesis of many diseases. Non secretory status of ABO blood groupantegens is related with higher incidence of autoimmune inflammatory disease which include seronegative spondyloarthropathyes. Increased frequency of seronegative spondyloarthropathies among people who have the HLA-B27 antigen is starting point of the view that genetic factors in combination with environmental factors influence the occurence of seronegative spondyloarthropathies in genetically predisposed individuals. The tesis explores the significance of the hemagglutionation inhibition test of saliva and determination of ABO and Lewis antigens in diagnostics of seronegativespondyloarthropathyes. Goals and hypothesis: The aim of this study was to determine the frequency of non secretors and secretors of ABO blood group antigens and Lewis phenotype in a group of patient with seronegative spondyloarthropathies and make comparsion to the healthy examined group. It was assumed that there is a significantly higher number of non secretors of ABO blood group antigens among the patients with seronegative spondyloarthropathies compared to healthy examined persons. It was assumed that there is a significantly higher number of non secretors of ABO blood group antigens among the patients with seronegative spondyloarthropathies who do not have HLA-B27 antigen. It was assumed that in patients with seronegative spondyloarthropathies Lewis phenotype on erythrocits can be changed in relation to the secretory status in the saliva. Methods: We performed a prospective longitudinal study. Respondants older than six years of both gender were divided into two randomized groups. Experimental group is consisted of 110 patients diagnosed with seronegative spondyloarthropathy. The control group consisted of 103 blood donors who did not have diagnosed disease from the group of seronegative spondyloarthropathies. To the subjects of the control and experimental groups was determined ABO blood group antigens, secretory status and Lewis phenotype, while to the subjects of experimental group also was designated HLA-B27 phenotype. Including criteria other than the above were that among female respondants were not pregnant, and that both groups of respondants did not receive a blood transfusion three months before joining the study. Results: The resuts of the study showed that non secretors of ABO blood group antigens have a 1,63 times higher rise (higher incidence) of developing disease from the group of seronegative spondyloarthropathies compared to a healthy population of subjects, as well as that decreased expression of Lewis antigens (b) represents a contributing factor for development of seronegativespondyloarthropathies. It was found that under the influence of seronegative spondyloarthropathies there are changes in Lewis phenotype on erythrocytes of patients. It was found that under the influence of seronegative spondyloarthropathies there are changes in Lewis phenotype on erythrocytes of patients. Probability for confirmation seronegative spondyloarthropathies is higher for 11% among non secretors who have HLA-B27 negative phenotype in comparison to non secretors who have HLA-B27 positive phenotype. Conclusion: Secretory status and Lewis phenotype are separate diagnostic biochemical markers independent of HLA-B27 antigen that contribute to the early detection of people who have a predisposition of the disease from the group of seronegative spondyloarthropathies.</p>
|
Page generated in 0.068 seconds